IAS: Outstanding Questions
Information on discussion around the draft of procedures of operation of information analytical system (IAS) of drug public purchase control has already been posted here.
Members of the Union of Professional Pharmaceutical Organizations consider that the draft needs elaboration and further detailing, and in some cases, specification. The same opinion is held by representatives of the Association of Russian Pharmaceutical Manufacturers concerned over statements on maximum level of profitability, a suggestion to come back from the indicative method of price calculation to the cost-based, as well as risks involved in switching to reference pricing
The Ministry of Economy of the Russian Federation also has objections against the draft suggested by the Ministry of Health. According to Evgeniy Yelin, Deputy Minister of Economy, the method suggested by the Ministry of health is quite obtuse, and more comprehensible approaches are needed. Besides, according to the Ministry of Economy, introduction of a single reference price for the drug in Russia renewable twice a year, as is suggested by the MoH, would not reflect the actual market prices. They will be either overstated or understated in regions, causing cost overrun and will make purchase impossible. There are other unresolved questions related to the project. It requires finalization.